Recombinant alpha-2-interferon for hairy cell leukemia.

Abstract

Twenty-two patients with hairy cell leukemia were treated with biosynthetic (recombinant) alpha-2-interferon in an open-label, single-arm efficacy study. Patients received 2 X 10(6) U/m2 recombinant alpha-2-interferon three times weekly. Therapy was well tolerated subjectively with minimal short-term hematologic toxicity. Two patients had bacterial infections during the period of study, and one patient experienced a short-lived readily reversible rejection of a corneal transplant. Statistical comparison of the mean hematologic indices at study entry and after three to six months of therapy with recombinant alpha-2-interferon indicates a significant improvement in hemoglobin, granulocyte, and platelet counts. Bone marrow biopsies in six of 14 patients after six months of therapy showed a greater than 50% decrease in the infiltration of leukemia cells. We conclude that recombinant alpha-2-interferon is highly effective therapy for hairy cell leukemia.

• Authors: A D Jacobs, R E Champlin, D W Golde
• Journal: Blood (Blood) Vol. 65 Issue 4 Pg. 1017-20 (Apr 1985) ISSN: 0006-4971 [Print] United States
• PMID: 3884059 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Interferon Type I

Topics

• Adult
• Aged
• Clinical Trials as Topic
• Corneal Transplantation
• Female
• Graft Rejection
• Humans
• Interferon Type I (adverse effects, therapeutic use, toxicity)
• Leukemia, Hairy Cell (drug therapy)
• Male
• Middle Aged